Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.72 |
| ▸ | DRD4 | P21917 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.63 |
| ▸ | HTR3A | P46098 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dazopride SCHEMBL7339808 | 0.99 | HTR4 (0.71) | HTR4DRD4CYP1A2CYP3A4ADRA2A | |
| Dazopride SCHEMBL10637099 | 0.95 | HTR4 (0.66) | HTR4DRD4CYP1A2CYP3A4ADRA2A | |
| Dazopride SCHEMBL121513 | 0.94 | CYP3A4 (0.68) | HTR4DRD4CYP1A2CYP3A4ADRA2A | |
| SCHEMBL7337602 | 0.87 | HTR4 (0.71) | HTR4 | |
| SCHEMBL7345151 | 0.85 | DRD4 (0.72) | HTR4DRD4CYP1A2CYP3A4ADRA2A | |
| SCHEMBL10634061 | 0.85 | DRD4 (0.64) | DRD4CYP1A2CYP3A4ADRA2ACYP2D6 | |
| SCHEMBL10637660 | 0.85 | HTR4 (0.53) | HTR4 | |
| SCHEMBL15650737 | 0.84 | HTR4 (0.83) | HTR4DRD4CYP1A2CYP3A4ADRA2A | |
| SCHEMBL10827995 | 0.84 | HTR4 (0.67) | HTR4ADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL678433 | 0.83 | HTR4 (0.65) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-20210338647-A1 | Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-04 | — | — | US | claimed |
| EP-3856163-A1 | COMBINATION OF ACETYLCHOLINESTERASE INHIBITOR AND 5-HT4 RECEPTOR AGONIST AS NEUROPROTECTIVE AGENT IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Université de Caen Normandie (FR) | 2021-08-04 | — | — | EP | claimed |
| US-20210161894-A1 | Compositions and Methods for Modulating Liver Endothelial Cell Fenestrations | LE COUTEUR DAVID (AU) | 2021-06-03 | — | — | US | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3720506-A1 | COMPOSITIONS AND METHODS FOR MODULATING LIVER ENDOTHELIAL CELL FENESTRATIONS | Lecouteur, David (AU) | 2020-10-14 | — | — | EP | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| WO-2006011159-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING RABEPRAZOLE SODIUM WITH IMPROVED BIOAVAILABILITY | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-02-02 | — | — | WO | claimed |
| EP-1596838-A2 | ONCE A DAY ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR AND A PROKINETIC AGENT | Torrent Pharmaceuticals Ltd (IN) | 2005-11-23 | — | — | EP | claimed |
| WO-2005074931-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING (S) -PANTOPRAZOLE | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| WO-2004071374-A2 | ONCE A DAY ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITIONS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2004-08-26 | — | — | WO | claimed |
| US-4624961-A | LEARNING ENHANCEMENT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-11-25 | — | — | US | claimed |
| US-4207327-A | N-(4-Pyrazolidinyl)benzamides and their amino precursors | A. H. ROBINS COMPANY, INC. (US) | 1980-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338647-A1 | Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases | HTR4, ACHE, CHRNA4 | HTR4 1/4885DRD4 114/4885CYP1A2 1147/4885 |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | HTR4 263/4885DRD4 2677/4885CYP1A2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.